File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

TitleTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Authors
Issue Date2010
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal Of Clinical Oncology, 2010, v. 28 n. 19, p. 3107-3114 How to Cite?
AbstractPurpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer. © 2010 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/173361
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMonk, BJen_US
dc.contributor.authorHerzog, TJen_US
dc.contributor.authorKaye, SBen_US
dc.contributor.authorKrasner, CNen_US
dc.contributor.authorVermorken, JBen_US
dc.contributor.authorMuggia, FMen_US
dc.contributor.authorPujadeLauraine, Een_US
dc.contributor.authorLisyanskaya, ASen_US
dc.contributor.authorMakhson, ANen_US
dc.contributor.authorRolski, Jen_US
dc.contributor.authorGorbounova, VAen_US
dc.contributor.authorGhatage, Pen_US
dc.contributor.authorBidzinski, Men_US
dc.contributor.authorShen, Ken_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorVergote, IBen_US
dc.contributor.authorNam, JHen_US
dc.contributor.authorPark, YCen_US
dc.contributor.authorLebedinsky, CAen_US
dc.contributor.authorPoveda, AMen_US
dc.date.accessioned2012-10-30T06:29:38Z-
dc.date.available2012-10-30T06:29:38Z-
dc.date.issued2010en_US
dc.identifier.citationJournal Of Clinical Oncology, 2010, v. 28 n. 19, p. 3107-3114en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/173361-
dc.description.abstractPurpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer. © 2010 by American Society of Clinical Oncology.en_US
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.titleTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian canceren_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1200/JCO.2009.25.4037en_US
dc.identifier.pmid20516432-
dc.identifier.scopuseid_2-s2.0-77955491837en_US
dc.identifier.hkuros170836-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955491837&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume28en_US
dc.identifier.issue19en_US
dc.identifier.spage3107en_US
dc.identifier.epage3114en_US
dc.identifier.isiWOS:000279254300004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridMonk, BJ=7005780295en_US
dc.identifier.scopusauthoridHerzog, TJ=12796396700en_US
dc.identifier.scopusauthoridKaye, SB=35406438000en_US
dc.identifier.scopusauthoridKrasner, CN=6506757179en_US
dc.identifier.scopusauthoridVermorken, JB=35243765000en_US
dc.identifier.scopusauthoridMuggia, FM=35402155300en_US
dc.identifier.scopusauthoridPujadeLauraine, E=7005035415en_US
dc.identifier.scopusauthoridLisyanskaya, AS=26633925200en_US
dc.identifier.scopusauthoridMakhson, AN=6603227989en_US
dc.identifier.scopusauthoridRolski, J=6603757663en_US
dc.identifier.scopusauthoridGorbounova, VA=23990461400en_US
dc.identifier.scopusauthoridGhatage, P=6603244355en_US
dc.identifier.scopusauthoridBidzinski, M=6604042472en_US
dc.identifier.scopusauthoridShen, K=7201458163en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridVergote, IB=7006066615en_US
dc.identifier.scopusauthoridNam, JH=35272628500en_US
dc.identifier.scopusauthoridPark, YC=36448541100en_US
dc.identifier.scopusauthoridLebedinsky, CA=25932183400en_US
dc.identifier.scopusauthoridPoveda, AM=7007180976en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats